Novo Nordisk eyes over five blockbuster drug launches by 2030
Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at a Capital Markets Day in London.